GS-US-320-1092 A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects with Chronic Hepatitis B Virus Infection

NCT02932150

A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects with Chronic Hepatitis B Virus Infection

Associated Conditions

Infectious Disease

Principal Investigator

Sponsor

Gilead Sciences

The study will evaluate the safety, tolerability, and effectiveness of Tenofovir Alafenamide (TAF) against hepatitis B virus in all of the enrolled children and adolescent subjects.